8 January 2020 - The FDA has approved five generic versions of Humira — the world’s biggest-selling drug with global revenue of $20 billion — and two of them have come within the past six months.

But so far the generic biologic drugs (called “biosimilars’’ in industry parlance) have failed to lower costs and make the therapies more accessible to patients.

AbbVie, Humira’s manufacturer, kicked off 2020 with a price increase in excess of 7% on its mega-blockbuster brand-name treatment, which is used to treat rheumatoid arthritis, psoriasis and Crohn’s disease.

Read Washington Post article